Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

the clorox co. - CLX

CLX

Close Chg Chg %
122.10 0.20 0.16%

Open Market

122.30

+0.20 (0.16%)

Volume: 1.03M

Last Updated:

Aug 12, 2025, 2:00 PM EDT

Trade Now

Company Overview: the clorox co. - CLX

CLX Key Data

Open

$122.18

 Day Range

121.30 - 123.26

52 Week Range

117.35 - 171.37

 Market Cap

$14.93B

Shares Outstanding

122.31M

 Public Float

121.91M

Beta

0.49

 Rev. Per Employee

N/A

P/E Ratio

18.73

 EPS

$6.56

Yield

399.71%

 Dividend

$1.24

EX-DIVIDEND DATE

Aug 13, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.86M

  

CLX Performance

1 Week
 
 -2.23%
 
1 Month
 
 -3.52%
 
3 Months
 
 -9.40%
 
1 Year
 
 -14.64%
 
5 Years
 
 -45.56%
 

CLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔

About the clorox co. - CLX

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

CLX At a Glance

The Clorox Co.
1221 Broadway
Oakland, California 94612-1888
Phone 1-510-271-7000 Revenue 7.10B
Industry Household/Personal Care Net Income 810.00M
Sector Consumer Non-Durables 2025 Sales Growth 0.155%
Fiscal Year-end 06 / 2026 Employees 7,600
View SEC Filings

CLX Valuation

P/E Current 19.16
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.424
Price to Sales Ratio 2.101
Price to Book Ratio 45.894
Price to Cash Flow Ratio 15.212
Enterprise Value to EBITDA 12.756
Enterprise Value to Sales 2.51
Total Debt to Enterprise Value 0.164

CLX Efficiency

Revenue/Employee 934,736.842
Income Per Employee 106,578.947
Receivables Turnover 8.653
Total Asset Turnover 1.256

CLX Liquidity

Current Ratio 0.838
Quick Ratio 0.565
Cash Ratio 0.087

CLX Profitability

Gross Margin 44.961
Operating Margin 16.596
Pretax Margin 15.175
Net Margin 11.402
Return on Assets 14.321
Return on Equity 249.615
Return on Total Capital 25.023
Return on Invested Capital 25.735

CLX Capital Structure

Total Debt to Total Equity 908.411
Total Debt to Total Capital 90.083
Total Debt to Total Assets 52.437
Long-Term Debt to Equity 875.389
Long-Term Debt to Total Capital 86.809
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for The Clorox Co. - CLX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
7.11B 7.39B 7.09B 7.10B
Sales Growth
-3.19% +3.97% -4.01% +0.16%
Cost of Goods Sold (COGS) incl D&A
4.62B 4.52B 4.07B 3.91B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
224.00M 236.00M 235.00M 219.00M
Depreciation
193.00M 206.00M 206.00M 198.00M
Amortization of Intangibles
31.00M 30.00M 29.00M 21.00M
COGS Growth
+10.96% -2.12% -9.96% -3.88%
Gross Income
2.49B 2.87B 3.02B 3.19B
Gross Income Growth
-21.69% +15.25% +5.36% +5.59%
Gross Profit Margin
+35.05% +38.86% +42.65% +44.96%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.79B 2.04B 2.11B 2.02B
Research & Development
132.00M 139.00M 126.00M 121.00M
Other SG&A
1.66B 1.91B 1.98B 1.89B
SGA Growth
-7.62% +13.87% +3.18% -4.46%
Other Operating Expense
- - - -
-
Unusual Expense
(14.00M) 505.00M 187.00M (70.00M)
EBIT after Unusual Expense
710.00M 322.00M 729.00M 1.25B
Non Operating Income/Expense
(6.00M) 19.00M (228.00M) (70.00M)
Non-Operating Interest Income
5.00M 16.00M 23.00M 9.00M
Equity in Earnings of Affiliates
6.00M 4.00M 5.00M 4.00M
Interest Expense
97.00M 103.00M 103.00M 101.00M
Interest Expense Growth
- +4.30% +6.19% -1.94%
Gross Interest Expense
97.00M 103.00M 103.00M 101.00M
Interest Capitalized
- - - -
-
Pretax Income
607.00M 238.00M 398.00M 1.08B
Pretax Income Growth
-32.56% -60.79% +67.23% +170.85%
Pretax Margin
+8.54% +3.22% +5.61% +15.17%
Income Tax
136.00M 77.00M 106.00M 254.00M
Income Tax - Current - Domestic
88.00M 186.00M 150.00M 204.00M
Income Tax - Current - Foreign
43.00M 40.00M 56.00M 68.00M
Income Tax - Deferred - Domestic
4.00M (148.00M) (104.00M) (19.00M)
Income Tax - Deferred - Foreign
1.00M (1.00M) 4.00M 1.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
6.00M 4.00M 5.00M 4.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
471.00M 161.00M 292.00M 824.00M
Minority Interest Expense
9.00M 12.00M 12.00M 14.00M
Net Income
462.00M 149.00M 280.00M 810.00M
Net Income Growth
-34.93% -67.75% +87.92% +189.29%
Net Margin Growth
+6.50% +2.02% +3.95% +11.40%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
462.00M 149.00M 280.00M 810.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
462.00M 149.00M 280.00M 810.00M
EPS (Basic)
3.7526 1.2056 2.2549 6.5574
EPS (Basic) Growth
-33.63% -67.87% +87.04% +190.81%
Basic Shares Outstanding
123.11M 123.59M 124.17M 123.53M
EPS (Diluted)
3.7286 1.1999 2.2435 6.5172
EPS (Diluted) Growth
-33.15% -67.82% +86.97% +190.49%
Diluted Shares Outstanding
123.91M 124.18M 124.80M 124.29M
EBITDA
920.00M 1.06B 1.15B 1.40B
EBITDA Growth
-36.46% +15.54% +8.28% +21.46%
EBITDA Margin
+12.94% +14.39% +16.23% +19.68%

Snapshot

Average Recommendation HOLD Average Target Price 132.625
Number of Ratings 22 Current Quarters Estimate 0.913
FY Report Date 09 / 2025 Current Year's Estimate 6.17
Last Quarter’s Earnings 2.87 Median PE on CY Estimate N/A
Year Ago Earnings 7.72 Next Fiscal Year Estimate 6.964
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 18 15
Mean Estimate 0.91 1.54 6.17 6.96
High Estimates 1.20 1.77 6.95 7.76
Low Estimate 0.67 1.40 5.88 6.38
Coefficient of Variance 16.03 6.92 4.04 5.57

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 2 2 2
HOLD 15 15 15
UNDERWEIGHT 0 0 0
SELL 4 4 4
MEAN Hold Hold Hold

Insider Actions for The Clorox Co. - CLX

Date Name Shares Transaction Value
Apr 4, 2025 Luc Bellet EVP - Chief Financial Officer 12,178 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $147.91 per share 1,801,247.98
Jan 6, 2025 Christopher Judson Williams Director 18,259 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Esther S. Lee Director 12,310 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Esther S. Lee Director 12,208 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Pierre R. Breber Director 74 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Russell John Weiner Director 14,279 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Russell John Weiner Director 14,117 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Russell John Weiner Director 13,116 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Matthew J. Shattock Director 15,436 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Matthew J. Shattock Director 15,120 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Matthew J. Shattock Director 14,120 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Allan Douglas David Mackay Director 7,904 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Christopher Judson Williams Director 17,258 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Christopher Judson Williams Director 849 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $162.41 per share 137,886.09
Jan 6, 2025 Spencer Charles Fleischer Director 17,632 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Spencer Charles Fleischer Director 17,439 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Spencer Charles Fleischer Director 16,439 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Allan Douglas David Mackay Director 9,092 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Allan Douglas David Mackay Director 8,092 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Allan Douglas David Mackay Director 8,031 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

The Clorox Co. in the News